In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Biocartis SA gets €30mm via Series B

Executive Summary

Molecular diagnostics company Biocartis SA raised €30mm ($40.2mm) in its Series B financing to first-time backers Debiopharm Group and Johnson & Johnson Development Corp., which were joined by returning shareholders Aescap, Biovest, Advent Venture Partners, Biocartis employees, and Benaruca (the family investment firm of the company's co-founder and CEO Rudi Pauwels). Funding will support continued late-stage development of its diagnostics platform. A member of Debiopharm will join the Biocartis board.
Deal Industry
  • In Vitro Diagnostics
  • In Vitro Diagnostics
    • Chemistry, Immunoassay
    • Molecular Diagnostics & Genetic Testing
  • Biotechnology
    • Pharmacogenetics-Pharmacogenomics
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies